U.S. Large Molecule Drug Substance CDMO Market Size Worth USD 25.37 Billion by 2034 | CAGR: 7.5%
The U.S. large molecule drug substance CDMO market size is expected to reach USD 25.37 Billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Large Molecule Drug Substance CDMO Market Size, Share, Trends, Industry Analysis Report By Product, By Service, By Source , and By End-use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
A Protein Large Molecule Drug Substance CDMO offers a full array of services including development and cGMP manufacturing of complex biologics, a service area currently undergoing a transformation through adoption of continuous and intensified bioprocessing technologies. This overarching trend represents a technological and strategic displacement of classic batch-based operations by more integrated, automated platforms that increase productivity while decreasing facility size and increasing product uniformity. The adoption of perfusion cultures, continuous chromatography or single-use technologies results in simplified workflows and more flexible production schemes, which are a direct response to the demand for scalable and cost-effective manufacturing of future class therapeutics. As a result, CDMOs are making substantial investments in these next generation platforms to deliver enhanced process efficiency and accelerated scale-up to their clients and establish themselves as the go-to partners for innovators seeking competitive and rapid market introduction.
Expansion opportunities are also driven by broadening the service offering beyond standard monoclonal antibodies to include novel modalities. This require unique know-how and adaptable platform technologies. Dedicated capabilities for the production of new types of products including cell and gene therapies, bispecific antibodies, and antibody-drug conjugates are being established and consolidated by CDMOs. The shift necessitates investment in specialized analytics, viral vector production and conjugation processes to handle the molecular idiosyncrasies. Thus, with burgeoning pipelines of complex biologics, being able to deliver full end-to-end development and manufacturing is emerging as a vital point of difference, as sponsors seek out partners with demonstrated expertise for successfully navigating the unique technical and regulatory challenges of advanced biologics.
U.S. Large Molecule Drug Substance CDMO Market Report Highlights
- By product, the biologics segment held a dominant position in 2024, owing to increasing demand for monoclonal antibodies, cell and gene therapies, and novel biologics for oncology and autoimmune diseases.
- Based on service, contract manufacturing accounted for the largest share, due to increasing dependence of pharmaceutical and biotechnology companies on CDMOs for mass GMP-compliant production to speed up commercialization.
- On the basis of source, mammalian expression systems accounted for the majority of the market share, as these systems have been demonstrated to be suitable for the production of complex biologics like with high accuracy and safety including monoclonal antibodies and recombinant proteins.
- By application, the end use of biotech companies accounted for the largest share of the market, driven by their reliance on CDMOs for process development, clinical-scale supply, and commercial production to minimize infrastructure investments.
- Key players in the global market include AGC Biologics, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Lonza Group AG, Patheon Inc. (Thermo Fisher Scientific Inc.), Recipharm AB, Rentschler Biopharma SE, Samsung Biologics Co., Ltd., Sartorius AG, Siegfried Holding AG, Syngene International Limited, Wuxi Biologics (Cayman) Inc., and Zymo Research Corp.
Request a free sample copy or read the full market insights : U.S. large molecule drug substance CDMO market Report
Polaris Market Research has segmented the market report based on product, services, source, end-use, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
- Biologics
- Biosimilar
By Services Outlook (Revenue, USD Billion, 2020–2034)
- Contract Manufacturing
- Clinical
- Commercial
- Contract Development
- Cell Line Development
- Process Development
By Source Outlook (Revenue, USD Billion, 2020–2034)
- Mammalian
- Microbial
- Others
By End-Use Outlook (Revenue, USD Billion, 2020–2034)
- Biotech Companies
- CRO
- Others
